Abogen Biosciences

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Health & Biotech 04 Oct 2026, 08:22 AM IST

Novartis Agrees to Up to $7.8 Billion mRNA Deal With China’s Abogen

Novartis has struck a licensing and development agreement with Chinese biotech Abogen Biosciences that could be worth as much as $7.8 billion, underscoring the Swiss drugmaker’s push into next-generation cancer therapies. The deal centers on an mRNA-encoded T-cell engager, a highly targeted approach that has drawn intense interest from large pharmaceutical companies seeking to replenish pipelines and deepen exposure to innovative Chinese science.

By RDU Global Wire6 min read

Frontier AI & Machine LearningRecently

Scientists Push Mammoth Revival Plan as AI Accelerates De-Extinction Race

Scientists are advancing a high-profile effort to recreate woolly mammoth traits using artificial intelligence, gene editing and stem-cell engineering, reviving debate over how far climate-tech should go in rewriting nature. The project, led by biotech firm Colossal Biosciences, is being framed as both a scientific breakthrough and a test case for whether de-extinction can support ecosystem restoration rather than remain a headline-grabbing novelty.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Abogen Biosciences:

Novartis(1)China(1)